#1 Clinical Trials Search in Europe

Tafasitamab

Tafasitamab is an innovative drug being studied in clinical trials for various blood cancers, including diffuse large B-cell lymphoma (DLBCL) and other hematologic malignancies. This article explores the ongoing research into tafasitamab’s safety and effectiveness, often in combination with other medications, as a potential treatment option for patients with relapsed or refractory blood cancers.

Table of Contents

What is Tafasitamab?

Tafasitamab is a medication used to treat certain types of blood cancers. It is known by several names, including MOR00208, INCMOR00208, and Xmab5574[3]. Tafasitamab is a type of drug called a monoclonal antibody, which means it’s designed to target specific cells in your body[2].

What Conditions Does Tafasitamab Treat?

Tafasitamab is primarily used to treat several types of blood cancers, including:

  • Diffuse Large B-Cell Lymphoma (DLBCL): This is the most common type of non-Hodgkin lymphoma, a cancer that starts in white blood cells called lymphocytes[1].
  • Marginal Zone Lymphoma (MZL): This is a slower-growing type of non-Hodgkin lymphoma[4].
  • Chronic Lymphocytic Leukemia (CLL): A type of cancer that affects the blood and bone marrow[2].
  • Central Nervous System (CNS) Lymphoma: A rare type of non-Hodgkin lymphoma that affects the brain and spinal cord[5].

Tafasitamab is often used when other treatments have not worked or when the cancer has come back after previous treatment[1].

How Does Tafasitamab Work?

Tafasitamab works by targeting a protein called CD19, which is found on the surface of certain types of cancer cells, particularly B-cells (a type of white blood cell). By attaching to CD19, tafasitamab helps your immune system recognize and destroy these cancer cells[4].

How is Tafasitamab Administered?

Tafasitamab is given as an intravenous (IV) infusion, which means it’s delivered directly into your bloodstream through a vein. The treatment schedule typically involves:

  • Weekly infusions during the first few cycles of treatment
  • Infusions every other week in later cycles

The exact schedule may vary depending on your specific condition and treatment plan[3].

Combination Therapy with Tafasitamab

Tafasitamab is often used in combination with other medications to enhance its effectiveness. Some common combinations include:

  • Tafasitamab + Lenalidomide: This combination is frequently used for treating DLBCL[1].
  • Tafasitamab + Acalabrutinib: This combination is being studied for treating Marginal Zone Lymphoma[4].
  • Tafasitamab + Parsaclisib: This combination is being investigated for various types of non-Hodgkin lymphoma and CLL[2].

Ongoing Clinical Trials

Several clinical trials are currently underway to further investigate the effectiveness and safety of tafasitamab in various conditions and combinations. Some of these trials include:

  • A study combining tafasitamab with lenalidomide for newly diagnosed DLBCL patients[6].
  • An investigation of tafasitamab plus lenalidomide for relapsed CNS lymphoma[5].
  • A trial evaluating tafasitamab in combination with acalabrutinib for Marginal Zone Lymphoma[4].

Potential Side Effects

As with any medication, tafasitamab can cause side effects. Common side effects may include:

  • Infusion-related reactions
  • Fatigue
  • Diarrhea
  • Cough
  • Fever

Your healthcare team will monitor you closely for any adverse reactions and adjust your treatment as necessary[7].

Aspect Details
Primary Cancers Studied Diffuse Large B-cell Lymphoma (DLBCL), Marginal Zone Lymphoma (MZL), Chronic Lymphocytic Leukemia (CLL)
Common Drug Combinations Tafasitamab + Lenalidomide, Tafasitamab + Acalabrutinib, Tafasitamab + Parsaclisib
Administration Method Intravenous infusion
Typical Dosing Schedule Weekly for first 3 cycles, then every other week
Key Efficacy Measures Overall Response Rate (ORR), Complete Response Rate (CRR), Duration of Response (DoR), Progression-Free Survival (PFS)
Primary Safety Measures Incidence and severity of Treatment-Emergent Adverse Events (TEAEs), Dose-Limiting Toxicities (DLTs)
Novel Research Areas CNS lymphoma, Blood-brain barrier permeability, Combination with other targeted therapies

FAQ

  • What is tafasitamab? Tafasitamab is an anti-CD19 monoclonal antibody being studied as a treatment for various blood cancers, particularly B-cell lymphomas. It targets the CD19 protein found on the surface of B cells.
  • What types of cancer is tafasitamab being studied for? Tafasitamab is being investigated for several hematologic malignancies, including diffuse large B-cell lymphoma (DLBCL), marginal zone lymphoma (MZL), and chronic lymphocytic leukemia (CLL).
  • How is tafasitamab administered in clinical trials? In most trials, tafasitamab is given intravenously (through a vein) on a specific schedule, often weekly for the first few cycles and then every other week in later cycles.
  • What are some common drug combinations being studied with tafasitamab? Tafasitamab is frequently studied in combination with other drugs, such as lenalidomide, acalabrutinib, and parsaclisib. These combinations aim to enhance the treatment's effectiveness against blood cancers.
  • What are researchers looking to measure in tafasitamab clinical trials? Researchers are primarily assessing the safety and efficacy of tafasitamab. Key measures include overall response rate, duration of response, progression-free survival, and the incidence of adverse events.

Ongoing Clinical Trials on Tafasitamab

  • Study on Methotrexate, Tafasitamab, Lenalidomide, and Rituximab for Patients with Primary Central Nervous System Lymphoma Not Eligible for Stem Cell Transplant

    Not recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Germany

  • Study on the Safety and Effectiveness of Tafasitamab and Lenalidomide for Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

    Not recruiting

    1 1 1 1
    Investigated drugs:
    Bulgaria Croatia Czechia Denmark Finland Hungary +4

  • Study on Lenalidomide, Tafasitamab, and Rituximab for Treating Diffuse Large B-Cell Lymphoma in Patients Aged 80 and Older

    Not recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium France

  • Study of Tafasitamab, Lenalidomide, and Rituximab for Patients with Relapsed or Refractory Follicular or Marginal Zone Lymphoma

    Not recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Austria Belgium Czechia Denmark Finland France +10

  • Study for Patients with Advanced Malignancies: Continued Treatment with Parsaclisib Alone or with Itacitinib, Ruxolitinib, Ibrutinib, or Tafasitamab

    Not recruiting

    1 1 1
    Investigated drugs:
    Belgium Czechia Denmark France Italy Poland +2

Glossary

  • Hematologic Malignancies: Cancers that affect the blood, bone marrow, and lymph nodes. These include various types of leukemia, lymphoma, and myeloma.
  • Diffuse Large B-cell Lymphoma (DLBCL): An aggressive type of non-Hodgkin lymphoma that affects B lymphocytes, a type of white blood cell.
  • Relapsed/Refractory: Refers to cancer that has returned after treatment (relapsed) or has not responded to initial treatment (refractory).
  • CD19: A protein found on the surface of B cells, which is targeted by tafasitamab.
  • Monoclonal Antibody: A type of protein made in the laboratory that can bind to substances in the body, including cancer cells. Used in cancer treatment and diagnosis.
  • Overall Response Rate (ORR): The percentage of patients whose cancer shrinks or disappears after treatment.
  • Progression-Free Survival (PFS): The length of time during and after treatment that a patient lives with the disease without it worsening.
  • Adverse Events: Any unfavorable and unintended sign, symptom, or disease temporarily associated with the use of a medical treatment or procedure.
  • Dose-Limiting Toxicity (DLT): Side effects of a drug that are severe enough to prevent an increase in dose or require a decrease in dose.
  • Pharmacokinetics: The study of how a drug is absorbed, distributed, metabolized, and eliminated by the body.

References